000141668 001__ 141668
000141668 005__ 20240229105128.0
000141668 0247_ $$2doi$$a10.1093/neuonc/noy064
000141668 0247_ $$2pmid$$apmid:29897562
000141668 0247_ $$2pmc$$apmc:PMC6178278
000141668 0247_ $$2ISSN$$a1522-8517
000141668 0247_ $$2ISSN$$a1523-5866
000141668 0247_ $$2altmetric$$aaltmetric:38344933
000141668 037__ $$aDKFZ-2018-01939
000141668 041__ $$aeng
000141668 082__ $$a610
000141668 1001_ $$aEllingson, Benjamin M$$b0
000141668 245__ $$aPost-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
000141668 260__ $$aOxford$$bOxford Univ. Press$$c2018
000141668 3367_ $$2DRIVER$$aarticle
000141668 3367_ $$2DataCite$$aOutput Types/Journal article
000141668 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1542895445_13155
000141668 3367_ $$2BibTeX$$aARTICLE
000141668 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141668 3367_ $$00$$2EndNote$$aJournal Article
000141668 520__ $$aIn the current study we used contrast-enhanced T1 subtraction maps to test whether early changes in enhancing tumor volume are prognostic for overall survival (OS) in newly diagnosed glioblastoma (GBM) patients treated with chemoradiation with or without bevacizumab (BV).Seven hundred ninety-eight patients (404 BV and 394 placebo) with newly diagnosed GBM in the AVAglio trial (NCT00943826) had baseline MRI scans available, while 337 BV-treated and 269 placebo-treated patients had >4 MRI scans for response evaluation. The volume of contrast-enhancing tumor was quantified and used for subsequent analyses.A decrease in tumor volume during chemoradiation was associated with a longer OS in the placebo group (hazard ratio [HR] = 1.578, P < 0.0001) but not BV-treated group (HR = 1.135, P = 0.4889). Results showed a higher OS in patients on the placebo arm with a sustained decrease in tumor volume using a post-chemoradiation baseline (HR = 1.692, P = 0.0005), and a trend toward longer OS was seen in BV-treated patients (HR = 1.264, P = 0.0724). Multivariable Cox regression confirmed that sustained response or stable disease was prognostic for OS (HR = 0.7509, P = 0.0127) when accounting for age (P = 0.0002), KPS (P = 0.1516), postsurgical tumor volume (P < 0.0001), O6-methylguanine-DNA methyltransferase status (P < 0.0001), and treatment type (P = 0.7637) using the post-chemoradiation baseline.The post-chemoradiation timepoint is a better baseline for evaluating efficacy in newly diagnosed GBM. Early progression during the maintenance phase is consequential in predicting OS, supporting the use of progression-free survival rates as a meaningful surrogate for GBM.
000141668 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000141668 588__ $$aDataset connected to CrossRef, PubMed,
000141668 7001_ $$aAbrey, Lauren E$$b1
000141668 7001_ $$aGarcia, Josep$$b2
000141668 7001_ $$aChinot, Olivier$$b3
000141668 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b4$$udkfz
000141668 7001_ $$aSaran, Frank$$b5
000141668 7001_ $$aNishikawa, Ryo$$b6
000141668 7001_ $$aHenriksson, Roger$$b7
000141668 7001_ $$aMason, Warren P$$b8
000141668 7001_ $$aHarris, Robert J$$b9
000141668 7001_ $$aLeu, Kevin$$b10
000141668 7001_ $$aWoodworth, Davis C$$b11
000141668 7001_ $$aMehta, Arnav$$b12
000141668 7001_ $$aRaymond, Catalina$$b13
000141668 7001_ $$aChakhoyan, Ararat$$b14
000141668 7001_ $$aPope, Whitney B$$b15
000141668 7001_ $$aCloughesy, Timothy F$$b16
000141668 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noy064$$gVol. 20, no. 11, p. 1525 - 1535$$n11$$p1525 - 1535$$tNeuro-Oncology$$v20$$x1523-5866$$y2018
000141668 909CO $$ooai:inrepo02.dkfz.de:141668$$pVDB
000141668 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000141668 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000141668 9141_ $$y2018
000141668 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000141668 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2017
000141668 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141668 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141668 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000141668 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000141668 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141668 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141668 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141668 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000141668 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bNEURO-ONCOLOGY : 2017
000141668 9201_ $$0I:(DE-He78)G370-20160331$$kG370$$lKKE Neuroonkologie$$x0
000141668 980__ $$ajournal
000141668 980__ $$aVDB
000141668 980__ $$aI:(DE-He78)G370-20160331
000141668 980__ $$aUNRESTRICTED